Association between adverse reactions to allopurinol and exposures to high maintenance doses: Implications for management of patients using allopurinol

Journal of Clinical Rheumatology

Volumn 19, Issue 4, 2013, Pages 180-186

  Paisansinsup, Tawatchai ^a   Breitenstein, Matthew K ^b   Schousboe, John T ^a,b  

^a PARK NICOLLET INSTITUTE   (United States)

^b Park Nicollet Institute for Research and Education   (United States)

Author keywords

Adverse reactions; Allopurinol maintenance dose; Gout

Indexed keywords

ALLOPURINOL; CREATININE;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; CREATININE BLOOD LEVEL; DISEASE ASSOCIATION; DRESS SYNDROME; ELECTRONIC MEDICAL RECORD; EOSINOPHILIA; FEMALE; GASTROINTESTINAL SYMPTOM; GOUT; HUMAN; KIDNEY FUNCTION; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; NEUROLOGIC DISEASE; PREDICTOR VARIABLE; PRESCRIPTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SIDE EFFECT; SKIN DISEASE; STEVENS JOHNSON SYNDROME; THROMBOCYTOPENIA;

AGED; ALLOPURINOL; CREATININE; DIARRHEA; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG HYPERSENSITIVITY; EOSINOPHILIA; FEMALE; FEVER; GOUT SUPPRESSANTS; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; NAUSEA; RETROSPECTIVE STUDIES; SEX FACTORS; STEVENS-JOHNSON SYNDROME; THROMBOCYTOPENIA; TRANSAMINASES; VOMITING;

EID: 84880049860     PISSN: 10761608     EISSN: 15367355     Source Type: Journal    
DOI: 10.1097/RHU.0b013e31829372e6     Document Type: Article

References (29)

1. Roddy E, Doherty M. Epidemiology of gout. Arthritis Res Ther. 2010;12:223. Available at: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3046529. Assessed December 21, 2010.
2. Zhu Y, Pandya BJ, Choi HK. Prevalence of gout and hyperuricemia in the US general population. The National Health and Nutrition Examination Survey 2007-2008. Arthritis Rheum. 2011;63:3136-3141.
3. Arromdee E, Michet CJ, Crowson CS, et al. Epidemiology of gout: is the incidence rising? J Rheumatol. 2002;29:2403-2406.
4. Demarco MAM, Maynard JW, Baer AN, et al. Diuretic use, increased serum urate levels, and risk of incident gout in a population-based study of adults with hypertension. Arthritis Rheum. 2012;64:121-129.
5. Keenan RT, O'Brien WR, Lee KH, et al. Prevalence of contraindications and prescription of pharmacologic therapies for gout. Am J Med. 2011;124:155-163.
6. Hande KR, Noone RM, Stone WJ. Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency. Am J Med. 1984;76:47-56.
7. Lee HY, Ariyasinghe JT, Thirumoorthy T. Allopurinol hypersensitivity syndrome: a preventable severe cutaneous reaction? Singapore Med J. 2008;49:385-387.
8. Zineh I, Mummaneni P, Lyndly J, et al. Allopurinol pharmacogenetics: assessment of potential clinical usefulness. Pharmacogenomics. 2011;12:1741-1749.
9. Lupton GP, Odom RB. The allopurinol hypersensitivity syndrome. J Am Acad Dermatol. 1979;1:365-374.
10. Singer JZ, Wallace SL. The allopurinol hypersensitivity syndrome. Unnecessary morbidity and mortality. Arthritis Rheum. 1986;29:82-87.
11. Lang PG Jr. Severe hypersensitivity reactions to allopurinol. South Med J. 1979;72:1361-1368.
12. *5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. PNAS. 2005;102:4134-4139.
13. Stamp LK, O'Donnell JL, Zhang M, et al. Starting dose is a risk factor for allopurinol hypersensitivity syndrome. A proposed safe starting dosing of allopurinol. Arthritis Rheum. 2012;64:2529-2536.
14. Vázquez-Mellado J, Morales EM, Pacheco-Tena C, et al. Relation between adverse events associated with allopurinol and renal function in patients with gout. Ann Rheum Dis. 2001;60:981-983.
15. Dalbeth N, Kumar S, Stamp L, et al. Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with gout. J Rheumatol. 2006;33:1646-1650.
16. Perez-Ruiz F, Liote F. Lowering serum uric acid levels: what is the optimal target for improving clinical outcomes in gout? Arthritis Care Res (Hoboken). 2007;57:1324-1328.
17. Khanna D, Fitzgerald JD, Khanna PP, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 1: systemic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res (Hoboken). 2012;64:1431-1446.
18. Reinders MK, Haagsma C, Jansen TLTA, et al. A randomized controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300-600 mg/day versus benzbromarone 100-200 mg/day in patients with gout. Ann Rheum Dis. 2009;68:892-897.
19. Stamp LK, O'Donnell JL, Zhang Mei, et al. Using allopurinol above the dose based on creatinine clearance is effective and safe in patients with chronic gout, including those with renal impairment. Arthritis Rheum. 2011;63:412-421.
20. Levey AS, Coresh J, Greene T, et al. Using standardized serum creatinine values in the Modification of Diet in Renal Disease Study equation for estimating glomerular filtration rate. Ann Intern Med. 2006;145:247-254.
21. Sackett DL. Bias in analytic research. J Chron Dis. 1979;32:51-63.
22. Emmerson BT, Hazelton RA, Frazer IH. Some adverse reactions to allopurinol may be mediated by lymphocyte reactivity to oxypurinol. Arthritis Rheum. 1988;31:436-440.
23. Puig JG, Casas EA, Ramos TH, et al. Plasma oxypurinol concentration in a patient with allopurinol hypersensitivity. J Rheumatol. 1989;16:842-844.
24. *5801 and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population. Pharmacogenet Genomics. 2009;19:704-709.
25. Jung JW, Song WJ, Kim YS, et al. HLA-B58 can help the clinical decision on starting allopurinol in patients with chronic renal insufficiency. Nephrol Dial Transplant. 2011;26:3567-3572.
26. Lonjou C, Borot N, Sekula O, et al, the RegiSCAR Study Group. A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high risk drugs. Pharmacogenet Genomics. 2008;18:99-107.
27. Young Jr JL, Boswell RB, Nies AS. Severe allopurinol hypersensitivity. Arch Intern Med. 1974;134:553-558.
28. Kim YW, Park BS, Ryu CH, et al. Allopurinol-induced aplastic anemia in a patient with chronic renal disease. Clin Nephrol. 2009;71:203-206.
29. Greenberg MS, Zambrano SS. Aplastic agranulocytosis after allopurinol therapy. Arthritis Rheum. 1972;15:413-416.